{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:31:40Z","timestamp":1793723500072,"version":"4.6.1"},"reference-count":45,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,4,11]],"date-time":"2008-04-11T00:00:00Z","timestamp":1207872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003\u2018Bepotastine besilate\u2019 is a novel second\u2010generation antihistamine developed in Japan and its antiallergic effects have already been demonstrated by various studies.<\/jats:p><jats:p>\u2022\u2003However, only a few clinical studies regarding its sedative property are available.<\/jats:p><jats:p>\u2022\u2003In addition, histamine H<jats:sub>1<\/jats:sub>receptor occupancy (H<jats:sub>1<\/jats:sub>RO) of this new antihistamine has never been measured by positron emission tomography (PET).<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003This paper provides the first measurement result of cerebral H<jats:sub>1<\/jats:sub>RO of bepotastine besilate (approximately 15%) as determined by PET.<\/jats:p><jats:p>\u2022\u2003This result is in accordance with the clinical classification of bepotastine as a second\u2010generation antihistamine.<\/jats:p><jats:p>\u2022\u2003In addition, the relationship between subjective sleepiness and cerebral H<jats:sub>1<\/jats:sub>RO of this second\u2010generation antihistamine is demonstrated for the first time using a placebo\u2010controlled crossover study design.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>Antihistamines are frequently used for treating various allergic diseases, but often induce sedation. The degree of sedation can be evaluated by measuring histamine H<jats:sub>1<\/jats:sub>receptor occupancy (H<jats:sub>1<\/jats:sub>RO) in the brain using positron emission tomography (PET). The aim was to measure H<jats:sub>1<\/jats:sub>RO of bepotastine, a new second\u2010generation antihistamine, and to compare it with that of diphenhydramine.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Eight healthy male volunteers (mean age\u2003\u00b1\u2003SD 24.4\u2003\u00b1\u20033.3\u2003years) were studied after single oral administration of bepotastine (10\u2003mg), diphenhydramine (30\u2003mg) or placebo, by PET imaging with<jats:sup>11<\/jats:sup>C\u2010doxepin in a crossover study design. Binding potential ratio and H<jats:sub>1<\/jats:sub>ROs were calculated using placebo data and were compared between bepotastine and diphenhydramine in the anterior and posterior cingulate gyri (ACG and PCG, respectively), superior and inferior frontal cortices (SFC and IFC, respectively), orbitofrontal cortex (OFC), insular cortex (IC), lateral and medial temporal cortices (LTC and MTC, respectively), parietal cortex (PC), occipital cortex (OC) and sensorimotor cortex (SMC). Plasma concentration of each antihistamine was measured, and its correlation to H<jats:sub>1<\/jats:sub>RO was examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>H<jats:sub>1<\/jats:sub>RO after bepotastine treatment was significantly lower than that after diphenhydramine treatment in all cortical regions (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). Mean H<jats:sub>1<\/jats:sub>ROs of bepotastine and diphenhydramine were 14.7% and 56.4%, respectively. H<jats:sub>1<\/jats:sub>ROs of both bepotastine and diphenhydramine correlated to their respective drug plasma concentration (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Oral bepotastine (10\u2003mg), with its relatively low H<jats:sub>1<\/jats:sub>RO and thus minimal sedation, has the potential for use as a mildly or slightly sedative antihistamine in the treatment of various allergic disorders.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03143.x","type":"journal-article","created":{"date-parts":[[2008,4,11]],"date-time":"2008-04-11T12:52:48Z","timestamp":1207918368000},"page":"811-821","source":"Crossref","is-referenced-by-count":62,"title":["Brain histamine H<sub>1<\/sub>receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with<sup>11<\/sup>C\u2010doxepin"],"prefix":"10.1111","volume":"65","author":[{"given":"Manabu","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayasu","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Funaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.06.008"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1034"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2003.01769.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1550"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(00)00039-3"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb16386.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702994"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01471.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004267590"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02514.x"},{"key":"e_1_2_6_12_2","first-page":"53","article-title":"[Phase I study of antiallergic agent, TAU\u2010284 (betotastine besilate): study of inhibitory effect on intradermal reaction of histamine]","volume":"13","author":"Ishibashi Y","year":"1997","journal-title":"J Clin Therap Med"},{"key":"e_1_2_6_13_2","first-page":"3","article-title":"[Phase I study of TAU\u2010284: single oral administration in healthy male volunteers]","volume":"13","author":"Yokota H","year":"1997","journal-title":"J Clin Therap Med"},{"key":"e_1_2_6_14_2","first-page":"13","article-title":"[Phase III study of TAU\u2010284 (betotastine besilate) on chronic urticaria: a multicenter double blind comparative study with placebo]","volume":"18","author":"Kawashima M","year":"2002","journal-title":"J Clin Therap Med"},{"key":"e_1_2_6_15_2","first-page":"576","article-title":"[Effect of betotastine besilate (TAU\u2010284), a novel anti\u2010allergic agent, on experimental allergic rhinitis]","volume":"46","author":"Murata T","year":"1997","journal-title":"Arerugi"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.110.19"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000028243"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-1811(03)00130-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01618.x"},{"key":"e_1_2_6_20_2","first-page":"1116","article-title":"Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate","volume":"47","author":"Kato M","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.0290s3147.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01183.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-0477.2001.01245.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.713"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9888(199812)33:12<1171::AID-JMS731>3.0.CO;2-#"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)90856-4"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.23.13316"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8043(00)00368-7"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/43\/2\/013"},{"key":"e_1_2_6_30_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03165298","article-title":"Performance evaluation of a large axial field\u2010of\u2010view PET scanner SET\u20102400w","volume":"11","author":"Fujiwara T","year":"1997","journal-title":"Ann Nucl Med"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-198302000-00008"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-199909000-00012"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2004.06.009"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.460020402"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00187-1"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.3.1144"},{"key":"e_1_2_6_37_2","volume-title":"Co\u2010planar Stereotaxic Atlas of the Human Brain.","author":"Talairach J","year":"1988"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02487.x"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.2.3.223"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1999.00008.x-i1"},{"key":"e_1_2_6_41_2","first-page":"64","article-title":"Positron emission tomographic study of central histamine H1\u2010receptor occupancy in human subjects treated with epinastine, a second\u2010generation antihistamine","volume":"17","author":"Yanai K","year":"1995","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00993.x"},{"key":"e_1_2_6_43_2","first-page":"143P","article-title":"In vivo cerebral histamine receptor occupancy of three antihistamine drugs: an 11C\u2010doxepin PET study","volume":"42","author":"Dogan AS","year":"2001","journal-title":"J Nucl Med"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007559"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0090-9556(24)15235-X","article-title":"OATP and P\u2010glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine","volume":"27","author":"Cvetkovic M","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.060194"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03143.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03143.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T16:42:29Z","timestamp":1738168949000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03143.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,11]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03143.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03143.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,11]]}}}